Figure 6.
Longitudinal changes in B-cell subsets after RTX therapy for an acute iTTP episode or ADAMTS13 relapse (ADAMTS13 activity 15%) until subsequent ADAMTS13 relapse, compared with patients who remained in remission over an equivalent period.
Longitudinal changes in B-cell subsets after RTX therapy for an acute iTTP episode or ADAMTS13 relapse (ADAMTS13 activity 15%) until subsequent ADAMTS13 relapse, compared with patients who remained in remission over an equivalent period.